IL-5 [Biotinylated] : IL-5Rα Inhibitor Screening ELISA Kit

Interleukin (IL)-5 is produced and secreted by T cells and mast cellsa critical,and is the important regulator of eosinophils and a therapeutic target for asthma. The pharmaceutical inhibition of IL-5 has been shown to reduce eosinophil counts and ameliorate asthmatic symptoms in studies on animal models of allergy as well as in human clinical trials. There are currently three commercially available IL-5 inhibitors in the United States. These include reslizumab (trade name Cinqair), benralizumab (trade name Fasenra), and mepolizumab (trade name Nucala). All three medications have been approved by the FDA for the treatment of severe eosinophilic asthma.

1. Unopened kit should be stored at 2°C-8°C upon receiving. 2. Find the expiration date on the outside packaging and do not use reagents past their expiration date. 3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new IL-5 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human IL-5 to immobilized human IL-5 R alpha in a functional ELISA assay, and employs a simple colorimetric sandwich ELISA platform.